systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-409Research ArticleМНЕНИЕ ЭКСПЕРТОВ / EXPERT OPINIONСердечно-сосудистые и онкологические заболевания: поиск решений новых проблемCardioncology: management of arterial hypertension in patients with cancer on chemotherapyЧазоваИ. Е.ChazovaI. E.noemail@neicon.ruОщепковаЕ. В.OschepkovaE. V.noemail@neicon.ruКирилловаМ. Ю.KirillovaM. Yu.noemail@neicon.ruШариповаГ. Х.SharipovaG. Ch.register.ihd.rus@gmail.comИнститут клинической кардиологии им. А.Л.Мясникова ФГБУ Российский кардиологический научно-производственный комплекс Минздрава РоссииРоссияA.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian FederationRussian Federation20152312202212267Copyright © Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю., Шарипова Г.Х., 20222022Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю., Шарипова Г.Х.Chazova I.E., Oschepkova E.V., Kirillova M.Y., Sharipova G.C.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/409ReferencesCarver J.R, Szalda D, Ky B. Asymptomatic cardiac toxicity in long - term cancer survivors: defining the population and recommendations for surveillance. Semin Oncol 2013; 40: 229-38.Carver J.R, Szalda D, Ky B. Asymptomatic cardiac toxicity in long - term cancer survivors: defining the population and recommendations for surveillance. Semin Oncol 2013; 40: 229-38.Sawaya H, Sebag I, Plana J et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596-603.Sawaya H, Sebag I, Plana J et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596-603.Bar-Joseph H, Ben-Aharon I, Tzabari M et al. In vivo bioimaging as a novel strategy to detect doxorubicin - induced damage to gonadal blood vessels. PLoS One 2011; 6: e23492.Bar-Joseph H, Ben-Aharon I, Tzabari M et al. In vivo bioimaging as a novel strategy to detect doxorubicin - induced damage to gonadal blood vessels. PLoS One 2011; 6: e23492.Chaosuwannakit N, D’Agostino R, Hamilton C.A et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2010; 28: 166-72.Chaosuwannakit N, D’Agostino R, Hamilton C.A et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2010; 28: 166-72.Drafts B.C, Twomley K.M, D’Agostino R Jr et al. Low to moderate dose anthracycline - based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013; 6: 877-85.Drafts B.C, Twomley K.M, D’Agostino R Jr et al. Low to moderate dose anthracycline - based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013; 6: 877-85.Kalabova H, Melichar B, Ungermann L et al. Intima - media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline - based chemotherapy. Med Oncol 2011; 28: 1281-7.Kalabova H, Melichar B, Ungermann L et al. Intima - media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline - based chemotherapy. Med Oncol 2011; 28: 1281-7.Mizia-Stec K, Goscinska A, Mizia M et al. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiol Pol 2013; 71: 681-90.Mizia-Stec K, Goscinska A, Mizia M et al. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiol Pol 2013; 71: 681-90.Сardinale D, Colombo A, Torrisi R et al. Trastuzumab - induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910-6.Сardinale D, Colombo A, Torrisi R et al. Trastuzumab - induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910-6.Ky B, Putt M., Sawaya H. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes and trastuzumab. JACC 2014; 63 (8): 809-16.Ky B, Putt M., Sawaya H. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes and trastuzumab. JACC 2014; 63 (8): 809-16.Чазова И.Е., Ощепкова Е.В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002- 2012 гг. Вестн. РАМН. 2013; 2: 4-11.Чазова И.Е., Ощепкова Е.В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002- 2012 гг. Вестн. РАМН. 2013; 2: 4-11.Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно - сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54 (10): 4-12.Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно - сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54 (10): 4-12.Chu T.F, Rupnick M.A, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.Chu T.F, Rupnick M.A, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.Rini B.I, Cohen D.P, Lu D.R et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763-73Rini B.I, Cohen D.P, Lu D.R et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763-73Wijermans P.W, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9-17.Wijermans P.W, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9-17.Sane D.C, Anton L, Brosnihan K.B. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201.Sane D.C, Anton L, Brosnihan K.B. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201.Chu T.F, Rupnick M.A. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.Chu T.F, Rupnick M.A. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.Veronese M.L, Mosenkis A, Flaherty K.T et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363-9.Veronese M.L, Mosenkis A, Flaherty K.T et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363-9.Maitland M.L, Bakris G.L, Black H.R et al. Initial assessment, surveil - lance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.Maitland M.L, Bakris G.L, Black H.R et al. Initial assessment, surveil - lance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.Copur M.S, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151-6.Copur M.S, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151-6.Nazer B, Humphreys B.D, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687-91.Nazer B, Humphreys B.D, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687-91.Schmidt A, Gruber U, Bohmig G et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034-7.Schmidt A, Gruber U, Bohmig G et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034-7.Fujihara C.K, Noronha I.L, Malheiros Antunes G.R et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283-90.Fujihara C.K, Noronha I.L, Malheiros Antunes G.R et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283-90.Grossman E.M.F. Management of drug - induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams & Wilkins, 2003; p. 516-9.Grossman E.M.F. Management of drug - induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams & Wilkins, 2003; p. 516-9.Luft F.C. Erythropoietin and arterial hypertension. Clin Nephrol 2000; 53: S61-4.Luft F.C. Erythropoietin and arterial hypertension. Clin Nephrol 2000; 53: S61-4.
The authors declare that there are no conflicts of interest present.